Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014937 · ClinicalTrials.gov registry record · NA
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT00014937: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00014937 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014937, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
Interventions
- DRUG lamivudine
- DRUG efavirenz
- DRUG lopinavir/ritonavir
- DRUG stavudine
- DRUG lamivudine/zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Phase | NA |
What the finished NCT00014937 record still lists
NCT00014937 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which lamivudine is the first listed.
NCT00014937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014937 about?
NCT00014937 is a clinical study titled "Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen". ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluat...
What is the current status of trial NCT00014937?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants.
What interventions are being tested in trial NCT00014937?
The interventions under investigation include: lamivudine (DRUG), efavirenz (DRUG), lopinavir/ritonavir (DRUG), stavudine (DRUG), lamivudine/zidovudine (DRUG).
Who is sponsoring clinical trial NCT00014937?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00014937's enrollment target sits among peer trials
240 440th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence